The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines - Preclinical and clinical trials have demonstrated proof-of-concept for the LT-IS patch. - BioPharm

ADVERTISEMENT

The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines
Preclinical and clinical trials have demonstrated proof-of-concept for the LT-IS patch.


BioPharm International


For the clinical evaluation, 160 human subjects were given a 50 μg LT dose in either a wet or dry patch. Each subject was immunized twice, at Day 0 and Day 21. Blood serum samples were collected from each subject on Days 7, 14, 21, 28, 35, and 42, for determination of LT IgG and LT IgA titers.


Figure 5. Human subjects received either a "wet" or "dry" patch containing 50μg LT on Day 0 and Day 21. LT IgG titers were measured on Days 7, 14, 21, 28, 35, and 42, and compared to baseline titers. The mean fold rise in LT IgG is indicated by the red and blue lines for the "dry" and "wet" patch, respectively.
Factorial analysis using LT IgG titers and fold rise (ratio to baseline titers) indicated that the dry patch produced statistically significantly higher titers and fold ratios of LT IgG and IgA than did the wet patch at all timepoints from Day 14 onward (Figure 5). This study demonstrated that the dry LT patch is equal to or better than the wet patch at the same dosage in terms of vaccine delivery. We surmise that the dry patch formulation is readily solubilized by transepidermal water loss, resulting in a greater LT concentration gradient at the surface of the skin compared to the wet patch. This higher concentration gradient provides the thermodynamic driving force to deliver more adjuvant into the skin.

Dry Formulation Optimization and Patch Design


Figure 6. Schematic representation of the IS patch showing patch components and application to the arm.
Since the clinical trial involving the dry versus wet patches, our laboratory has continued to optimize the dry formulation matrix and to develop the final patch format for transcutaneous delivery. To this end, our current dry patch contains a proprietary stabilizing matrix that is compatible with biological molecules and vaccine antigens. The dry patch is prepared by dosing a small volume (20–40 μL) of the drug substance blend onto an absorbent matrix with a surface area ranging from 1–3 cm2 , followed by drying under moderate conditions in a convection oven. The LT-dosed matrix is assembled with an occlusive backing, release liner and adhesive overlay, and sealed in a nitrogen-purged foil pouch for storage at 2–8 C (Figure 6). When applied to the skin, the dry patch formulation is readily hydrated by skin moisture (transepidermal water loss) and effectively releases the antigens, adjuvant, or both into the skin. The patch is removed after six hours of wear.

LT Dry Patch Thermostability

The drug substance(s) and excipients are extracted from the patch and this extract is then used in the various analytical assays. Only key stability-indicating assays will be discussed in this paper.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here